Clinical trials: B Cell
Diffuse Large B-Cell Lymphoma, B-Cell Malignancies
A Study Investigating the Safety and How the Trispecific T-Cell Engaging Antibody BG-T0050 Works in Adults With Diffuse Large B-cell Lymphoma (DLBCL) and Other Aggressive B-Cell Malignancies
The purpose of this study is to test the safety and tolerability of BG-T0050 and to identify the recommended dose and dosing schedule (including dose levels and timing) that can be taken without having serious side effects in…
- Trial name
- NCT07881211
- Testing
- BG-T0050
- Volunteers
- 70 people
- Sponsor
- BeOne Medicines
Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia
Study of Hypoxia-Activated Prodrug TH-302 to Treat Advanced Leukemias
The primary objective of this study is to determine the maximum tolerated dose, dose limiting toxicity, safety and tolerability of TH-302 in patients with acute leukemias, advanced phase chronic myelogenous leukemia (CML), high…
- Conditions
- Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, High-risk Myelodysplastic Syndrome
- Trial name
- NCT01149915
- Testing
- TH-302
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Threshold Pharmaceuticals
Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin
A Phase 1b Open-label Study to Evaluate the Safety and Efficacy of CC-122 With Obinutuzumab (GA101) in Relapsed/Refractory DLBCL and iNHL.
CC-122-NHL-001 study is a multicenter, open-label, phase Ib study with dose escalation and expansion parts. It evaluates the safety, tolerability and clinical pharmacokinetics of CC-122 in combination with obinutuzumab (GA101).
- Trial name
- NCT02417285
- Testing
- Obinutuzumab, CC-122
- Where
- 8 sites in France, Italy and 1 more
- Volunteers
- 75 people
- Sponsor
- Celgene
Refractory B-Cell Lymphoma
Study of Anti-CD19 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma
This is a single-centre, single-arm and open-label study to investigate the safety and efficacy of anti CD19 CAR NK cells in patients with relapsed refractory B cell lymphoma.
- Trial name
- NCT03690310
- Testing
- Anti-CD19 CAR NK Cells
- Volunteers
- 9 people
- Sponsor
- Allife Medical Science and Technology Co., Ltd.
Chronic Lymphocytic Leukemia
Kinetic Biomarker for Chronic Lymphocytic Leukemia Prognosis
This project will attempt to validate the utilization of a stable isotope kinetic biomarker (KineMarkerTM) as a predictive test for disease progression in early stage chronic lymphocytic leukemia (CLL).
- Trial name
- CRC011 (NCT00481858)
- Where
- 5 sites in United States
- Volunteers
- 150 people
- Sponsor
- KineMed
B-cell Malignancies
Immune Response to Influenza Vaccine in Adults With B-cell Malignancies Treated With Idelalisib
The primary objective of this study is to assess the immune response to an influenza vaccine in adults with B-cell malignancies who are currently receiving treatment with idelalisib in a Gilead-sponsored study (parent study).
- Trial name
- NCT03701438
- Testing
- Influenza Vaccine
- Where
- 2 sites in Czechia, Spain
- Volunteers
- 2 people
- Sponsor
- Gilead Sciences
Relapsed or Refractory B-cell Malignancy(NHL/ALL)
A Study of ET-02 in Patients With Relapsed or Refractory B-cell Malignancy(NHL/ALL)
The purpose of this study is to evaluate the safety and efficacy of CD19-UCART in patients with r/r B-cell hematological malignancies.
- Trial name
- NCT04933825
- Testing
- ET-02
- Where
- China
- Volunteers
- 18 people
- Sponsor
- EdiGene (GuangZhou) Inc.
Non-Hodgkins Lymphoma, B-cell Lymphoma
Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
The purpose of this study is to determine whether ublituximab is safe and effective in patients with relapsed or refractory B-cell lymphoma who were previously treated with rituximab.
- Conditions
- Non-Hodgkins Lymphoma, B-cell Lymphoma, Waldenstrom's Macroglobulinemia, Marginal Zone Lymphoma
- Trial name
- NCT01647971
- Testing
- Ublituximab
- Where
- 8 sites in United States
- Volunteers
- 39 people
- Sponsor
- TG Therapeutics, Inc.
Chronic Lymphocytic Leukemia
Safety, Effectiveness and Patient Acceptance of the Treatment With MabCampath in Chronic Lymphocytic Leukemia
This study will collect data on safety, effectiveness and patient acceptance of MabCampath treatment under daily life conditions.
- Trial name
- NCT00836043
- Testing
- Alemtuzumab (MabCampath)
- Where
- 3 sites in Bosnia and Herzegovina, Israel and 1 more
- Volunteers
- 6 people
- Sponsor
- Genzyme, a Sanofi Company
Lymphoma, Non-Hodgkin
A Study of DZD8586 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (TAI-SHAN1)
This study is designed to evaluate the safety, tolerability, pharmacokinetic profile, and antitumor efficacy of DZD8586 in participants with relapsed or refractory B-NHL.
- Trial name
- NCT05844956
- Testing
- DZD8586
- Where
- 6 sites in China
- Volunteers
- 17 people
- Sponsor
- Dizal Pharmaceuticals
Primary Sjögren's Syndrome
Study of Pharmacodynamic Effects of VAY736 in Patients With Primary Sjögren's Syndrome
This study consists of three consecutive parts. Part 1 in primary Sjögren's syndrome (pSS) patients (n=2-6) and Part 2 in healthy voluteers (n=3) are feasibility studies to assess if the selected [Zr-89]-rituximab PET/CT method…
- Trial name
- NCT02495129
- Testing
- VAY736 lower dose, VAY736 higher dose
- Sponsor
- Novartis Pharmaceuticals
Lymphoma, Mantle-Cell, Leukemia, Lymphocytic, Chronic, B-Cell
SCH 727965 in Patients With Mantle Cell Lymphoma or B-Cell Chronic Lymphocytic Leukemia (Study P04715)
Participants will be randomized to SCH 727965 or a comparator drug (bortezomib for mantle cell lymphoma [MCL] or alemtuzumab for B cell chronic lymphocytic leukemia [B CLL]).
- Trial name
- NCT00871546
- Testing
- SCH 727965, Bortezomib, Alemtuzumab
- Volunteers
- 8 people
- Sponsor
- Merck Sharp & Dohme LLC
B-cell Non-Hodgkin Lymphoma
Study of Welgenaleucel (UWC19) in Patients With Relapsed or Refractory B-cell Lymphoma
This is an open-label, single-center Phase 1/2 study with a dose-escalation phase (Part 1) and a cohort expansion phase (Part 2) in patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL).
- Trial name
- NCT04296461
- Testing
- Welgenaleucel
- Where
- Taiwan
- Volunteers
- 20 people
- Sponsor
- UWELL Biopharma
Diffuse Large B-Cell Lymphoma
A Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of Loncastuximab Tesirine in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated Diffuse Large B-cell Lymphoma (LOTIS-8)
The primary objective of this study is to characterize the safety and tolerability of loncastuximab tesirine in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy, and…
- Trial name
- LOTIS-8 (NCT04974996)
- Testing
- Loncastuximab tesirine, Prednisone, Rituximab
- Where
- United States
- Sponsor
- ADC Therapeutics S.A.
Leukemia, Lymphoma
VNP40101M in Treating Patients With Richter Syndrome or Refractory or Relapsed Chronic Lymphocytic Leukemia or Other Lymphoproliferative Disorders
RATIONALE: Drugs used in chemotherapy, such as VNP40101M, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00304005
- Testing
- laromustine
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Vion Pharmaceuticals
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO)
A Phase 3 clinical trial to examine the efficacy of duvelisib monotherapy versus ofatumumab monotherapy in subjects with relapsed or refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL).
- Trial name
- NCT02004522
- Testing
- Duvelisib, Ofatumumab
- Where
- 92 sites in United States, Australia and 9 more
- Volunteers
- 319 people
- Sponsor
- SecuraBio
Chronic Lymphocytic Leukemia
A Study of AZD6738 and Acalabrutinib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
This study evaluates the safety, pharmacokinetics, pharmacodynamics and efficacy of acalabrutinib and ceralasertib (known as AZD6738) when taken in combination.
- Trial name
- NCT03328273
- Testing
- Ceralasertib, Acalabrutinib
- Where
- 11 sites in Poland, United Kingdom
- Volunteers
- 12 people
- Sponsor
- Acerta Pharma BV
Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
A study of acalabrutinib plus venetoclax (AV) versus venetoclax plus obinutuzumab (VO) in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma.
- Trial name
- MAJIC (NCT05057494)
- Testing
- Acalabrutinib, Venetoclax, Obinutuzumab
- Where
- 37 sites in United States, Australia and 5 more
- Volunteers
- 607 people
- Sponsor
- AstraZeneca
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas
This study is being done to evaluate the safety, tolerability and effectiveness of Oral CG-806 for the treatment of patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or Non-Hodgkin's Lymphomas…
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Non-Hodgkin's Lymphoma
- Trial name
- NCT03893682
- Testing
- CG-806
- Where
- 30 sites in United States
- Volunteers
- 36 people
- Sponsor
- Aptose Biosciences Inc.
Diffuse Large B-Cell Lymphoma
A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
The overall purpose of the study is to determine if MEDI-551, when used in combination with salvage chemotherapy, Ifosfamide-carboplatin-etoposide (ICE) or Dexamethasone-cytarabine (DHAP) in patients with relapsed or refractory…
- Trial name
- NCT01453205
- Testing
- MEDI-551 2 mg/kg, Rituximab, ICE
- Where
- 81 sites in United States, Canada and 9 more
- Volunteers
- 187 people
- Sponsor
- MedImmune LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.